These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Clinical Benefit of Autologous Stem Cell Transplantation for Patients with Multiple Myeloma Achieving Undetectable Minimal Residual Disease after Induction Treatment. Liu J; Yan W; Fan H; Xu J; Li L; Du C; Mao X; Yan Y; Xu Y; Sui W; Deng S; Yi S; Anderson KC; Qiu L; Zou D; An G Cancer Res Commun; 2023 Sep; 3(9):1770-1780. PubMed ID: 37680953 [TBL] [Abstract][Full Text] [Related]
6. Predicting the Future: Machine-Based Learning for MRD Prognostication. Pawlyn C; Davies FE Clin Cancer Res; 2022 Jun; 28(12):2482-2484. PubMed ID: 35357437 [TBL] [Abstract][Full Text] [Related]
7. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma]. Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022 [No Abstract] [Full Text] [Related]
8. Impact of Post-Transplant Response and Minimal Residual Disease on Survival in Myeloma with High-Risk Cytogenetics. Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA Biol Blood Marrow Transplant; 2017 Apr; 23(4):598-605. PubMed ID: 28115277 [TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Garcés JJ; Cedena MT; Puig N; Burgos L; Perez JJ; Cordon L; Flores-Montero J; Sanoja-Flores L; Calasanz MJ; Ortiol A; Blanchard MJ; Rios R; Martin J; Martínez-Martinez R; Bargay J; Sureda A; de la Rubia J; Hernandez MT; Rodriguez-Otero P; de la Cruz J; Orfao A; Mateos MV; Martinez-Lopez J; Lahuerta JJ; Rosiñol L; Blade J; San-Miguel JF; Paiva B J Clin Oncol; 2022 Sep; 40(27):3151-3161. PubMed ID: 35666958 [TBL] [Abstract][Full Text] [Related]
13. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: a meta-analysis. Landgren O; Devlin S; Boulad M; Mailankody S Bone Marrow Transplant; 2016 Dec; 51(12):1565-1568. PubMed ID: 27595280 [TBL] [Abstract][Full Text] [Related]
15. MRD Testing in Multiple Myeloma: From a Surrogate Marker of Clinical Outcomes to an Every-Day Clinical Tool. Landgren O Semin Hematol; 2018 Jan; 55(1):1-3. PubMed ID: 29759146 [TBL] [Abstract][Full Text] [Related]
16. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. San-Miguel J; Avet-Loiseau H; Paiva B; Kumar S; Dimopoulos MA; Facon T; Mateos MV; Touzeau C; Jakubowiak A; Usmani SZ; Cook G; Cavo M; Quach H; Ukropec J; Ramaswami P; Pei H; Qi M; Sun S; Wang J; Krevvata M; DeAngelis N; Heuck C; Van Rampelbergh R; Kudva A; Kobos R; Qi M; Bahlis NJ Blood; 2022 Jan; 139(4):492-501. PubMed ID: 34269818 [TBL] [Abstract][Full Text] [Related]
17. Is molecular remission the goal of multiple myeloma therapy? Davies FE Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):205-211. PubMed ID: 29222257 [TBL] [Abstract][Full Text] [Related]
18. Longitudinal genetically detectable minimal residual disease by fluorescence Cui J; Yu T; Lv R; Liu J; Fan H; Yan W; Xu J; Du C; Deng S; Sui W; Ho M; Xu Y; Anderson KC; Dong X; Qiu L; An G Ther Adv Med Oncol; 2024; 16():17588359231221340. PubMed ID: 38249329 [TBL] [Abstract][Full Text] [Related]
19. [Impact of minimal residual disease detection after treatment of multiple myeloma]. Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098 [TBL] [Abstract][Full Text] [Related]
20. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Landgren O; Prior TJ; Masterson T; Heuck C; Bueno OF; Dash AB; Einsele H; Goldschmidt H; Knop S; Li C; Mellqvist UH; McFadden I; Oprea C; Ross JA; Talpes M; Hydren JR; Ahlstrom JM; Kazandjian D; Weinhold N; Zhang R; Stetler-Stevenson M; Marti G; Devlin SM Blood; 2024 Jul; 144(4):359-367. PubMed ID: 38768337 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]